We are sorry to announce that the ability to send us messages through See Your Chart, has been temporarily turned off. We will update this post when it is turned back on. If you are having login troubles, please click on FORGOT YOUR USERNAME OR PASSWORD.
A local health care company is investing $22 million in facility upgrades and new equipment, including “game-changing” technology that could help save lives.
Dayton Physicians Network, a multi-specialty medical group that provides cancer treatment and urological services, is expanding one of its facilities and renovating two others to make room for new radiation equipment. The expansions also will lead to new hires, with up to 30 employees added in the next year as a result of the project. The group currently employs 400 people at its Dayton-area facilities.
The upcoming expansion also could provide work for area builders and suppliers.
The physician network recently purchased imaging machines and linear accelerators, which can be used as radiation treatments for patients with cancer. The equipment will touch nearly every facility the network operates — seven locations from Greenville to Middletown — but the bulk of investment will occur at the Greater Dayton Cancer Center in Kettering, Atrium Medical Center in Middletown and Upper Valley Medical Center in Troy.
The equipment purchase was a joint venture with Dayton Physicians and Dayton-based Premier Health. The physician network leases space from Premier in a few of its hospitals, including Atrium and Upper Valley, but it is an independent group.
Dr. Gregory Rasp, medical director and radiation oncologist at DPN, said the new equipment will turn “good treatment into great treatment.”
“It’s going to allow for more accurate treatment, and more accurate treatment means better cure rates and lower complication rates,” Rasp said. “Basically, it will help us diagnose cancers better and treat them better.”
The imaging component will include new software called Smart Metal Artifact Reduction, which eliminates what medical professionals call “streaking.” Streaking is common in patients with fillings, artificial hips or other procedures involving the insertion of metal, which makes it difficult to visualize where a tumor starts and stops.
In addition, the equipment will allow physicians to more accurately position patients for treatment. This will cut down on errors that can occur if a patient moves during treatment, and helps doctors pinpoint the exact area needed for radiation therapy.
“With the newer equipment, the computer automatically adjusts for those shifts and rotations, and puts us right on the money with treatment,” Rasp said. “It’s kind of a game-changer because it allows us to treat a smaller area. Small areas mean less complications.”
The hope is enhanced treatment will decrease side effects and increase cure rates by 3 percent to 4 percent. Rasp said even if cure rates improve by just a few percentage points, it will save lives.
“Even if the cure rate stays the same, which we don’t anticipate, we can reduce the number of people having complications from the radiation,” he said. “It’s going to make it a lot easier on them and their families.”
The new equipment is expected to be installed in the first and second quarter of 2019, but before it is up-and-running, DPN must make some upgrades to its facilities.
At the Greater Dayton Cancer Center in Kettering, a new addition will be constructed onto the existing facility, and “significant remodeling” will occur at Upper Valley and Atrium, Rasp said. Wayne Cancer Center in Greenville also will be remodeled, though he said it will be less significant.
Each facility is likely to see an increase of 900 to 1,000 square feet, which include seven-foot-thick concrete walls needed to shield the radiation. Most of these walls are already constructed, though another “vault,” as Rasp described it, may need to be added at the Kettering center.
DPN has contracted with Dayton-based Sharp Conway Architects to design the project. Once the drawings are finalized, construction bids will be released. Rasp said the hope is one construction company will work on each facility.
Construction on each location will be staggered, and the first facility is expected to be completed in four to six months. Rasp said they’ll likely start in Middletown.
The facility upgrades and new equipment add to millions of dollars in investment DPN has been making in the last few years. Rasp said they’ve reinvested $18 million in the practice since 2012, and the latest project will bring them up to $40 million over a six-and-a-half year period.
“In a lot of groups, that money would just funnel to shareholders,” he said. “But we’ve always known that we need to reinvest it to be at the cutting edge of things, and in turn the practice grows. The other thing is we always put patients first over profits. I know that sounds like something every doctor says, but we’ve always had this belief that we need to have the highest quality standards for our patients.”
Urologist Michael Yu of Dayton Physicians Urology Answers Questions about Symptoms and Discusses
a Minimally Invasive Breakthrough Treatment Option
What Are the Symptoms of Enlarged Prostate and When Should Men See a Urologist?
Over 70% of men in their 60s have symptoms of enlarged prostate1. This can cause loss of productivity, interrupted sleep and, in some cases, can cause depression.2
Common symptoms include:
- Frequent need to urinate both day and night
- Weak or slow urinary stream
- A sense that you cannot completely empty your bladder
- Difficulty or delay in starting urination
- Urgent feeling of needing to urinate
- A urinary stream that stops and starts
Enlarged prostate can wreak havoc on a man’s quality of life, so it’s important to see a physician if these problems persist.
What Treatment Options Do You Recommend to Your Patients?
Treatment options for enlarged prostate range from medications to surgery, with minimally invasive options in between.
Medications can be helpful in relieving symptoms for some men, but patients must continue taking them long-term to maintain the effects. Some patients may suffer side effects including dizziness, headaches, or sexual dysfunction. And some may not get adequate relief of their symptoms.
Surgical options, such as transurethral resection of the prostate (TURP) or photovaporization of the prostate (PVP), are very effective. However, these typically require general anesthesia, overnight hospitalization, and post-operative catheterization. Surgery can also increase the risk of erectile dysfunction or loss of ejaculation.
Can You Describe What Minimally Invasive Treatments are Available?
I’m very excited to offer my patients a revolutionary treatment option called the UroLift® System treatment. The UroLift System treatment is a breakthrough, minimally invasive option to treat enlarged prostate. It does not require any cutting, heating, or removal of prostate tissue.
Here’s how it works: a urologist uses the UroLift System device to lift and move the enlarged prostate tissue out of the way so it no longer blocks the urethra (the passageway that urine flows through). Tiny implants are placed to hold the tissue in place, like tiebacks on a window curtain, leaving an unobstructed pathway for urine to flow normally again.
What are the Benefits of the UroLift® System?
I perform the UroLift System treatment in the hospital, which patients like. The treatment typically takes under an hour, preserves sexual function, doesn’t require cutting, heating or removal of tissue. Compared to other BPH surgeries, the UroLift System treatment has a strong safety profile with minimal side effects.3
Most common side effects are mild to moderate and include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and/or the inability to control the urge. Most symptoms resolved within two to four weeks after the procedure.
1. Berry, et al., J Urol 1984
2. Speakman et al., 2014 BJUI International
3. Roehrborn, et al., J Urology 2013
Congratulations to The University of Texas MD Anderson Cancer Center in Houston for being ranked America’s best cancer hospital for 2018, according to the annual rankings from US News and World Report.
We are affiliated with MD Anderson as our doctors are participating in MD Anderson Cancer Network®, a program of MD Anderson Cancer Center at Premier Health.
B.S. Washington and Lee University 2007, magna cum laude
M.D. Virginia Commonwealth University, Medical College of Virginia 2011
General Surgery Internship: The University of Chicago Medical Center 2011-2012
The University of Chicago Medical Center 2012-2017
IU Health Methodist Hospital, IU School of Medicine: 2017-2018
- Board Eligible Urology
- Benign prostatic hyperplasia (BPH)
- Stone disease
- Minimally invasive surgery for prostate and kidney cancer
- American Urological Association,
- Endourological Society
- American Medical Association
Currently seeing patients at the following locations:
- Miami Valley Hospital South
Dr. Anderson was born in Cincinnati, OH but spent his childhood in Virginia where he became an Eagle Scout prior to graduating from medical school. Dr. Anderson has various research publications in peer-reviewed journals and has presented numerous times at the American Urological Association (AUA) Annual Meeting, with award winning abstracts including a plenary. Dr. Anderson and his wife, who grew up in the Loveland/Milford area, are excited to return home to Ohio and raise their daughter in the Miami Valley community.
Did you know there was a shortage of urologists in the United States? The American Urological Association recognizes that there is a growing national shortage. This deficit is compounded by an aging U.S. population that will require more urologic care. The 65 and older population will comprise 17% of our population by 2020.
The projected number of urologists needed to meet the population needs in 2020 is 16,000. The number of practicing urologist in 2016 was 10,954. Over 50% of the urologists are currently over the age of 52. The projected number of practicing urologists will decrease to 7500 by 2020.
Compounding the workforce shortages are the challenges facing urology graduate medical education. There are currently 295 residency spots per year. The Balanced Budget Act of 1997 capped Medicare residency funding which means that money is one of the limiting factors affecting addition of any new residency spots. This issue applies to all surgical specialties.
Our mission at Dayton Physicians Network Urology is to provide you with the highest quality personalized urologic care in southwest Ohio. We currently see patients from 11 surrounding counties with a population of 1,762,366 people. We are fortunate to have 7 urologists and 5 specialized trained urology advanced practice providers to carry out our mission.
The manpower shortage does create some issues with wait times. Over 50% of our patients have complex medical problems or cancer and there is no way to predict a patient’s needs when they schedule an appointment. This means that not everyone fits into a 15-minute slot. We appreciate your patience and understanding as we try to care for our community’s urologic needs.
If you have any questions please ask for our Operations Manager. We wish all of you the best of health!
John, a 42-yr-old veteran, who was referred to me for the evaluation of low blood counts. Further testing including bone marrow biopsy revealed acute myeloid leukemia (AML, a type of blood cancer) transforming from a myelodysplastic syndrome (a bone marrow failure condition, often caused by exposure to chemicals or nuclear material). As an oncologist, I not only had to deliver the terrifying news, but also tell him that his condition carries poor prognosis with only 10% chance of cure. It did not take John that long to figure out he had 90% chance of dying. He really wanted to fight to see his unborn child. Unfortunately, chemotherapy did not work…he was finally succumbed to AML without even seeing his child. There are many like John who die from blood cancer everyday.
The treatment for leukemia and lymphoma has come a long way. In 1960s, blood cancer survival rate was only 3%. The cure rate for children with certain blood cancers now is around 85%, thanks to the research and donors like you. For adults, certain leukemias still carry a grim prognosis.
This year, I have been nominated for The Leukemia and Lymphoma Society (LLS) “Man of the Year” title which indeed is an honor. With your help and support, I am starting this journey along with my team members to raise $500,000 between March 1st and May 11th of 2018. Every dollar we raise opens the door for a new study and every study takes us a step closer to a “cure” for these desperate patients. 78% of funds raised in this campaign go directly to research and patient services, while 7% goes towards LLS administration and 15% for fundraising.
There are several ways you can help us reach our goal and they are attached with this letter. Please note that your donations/sponsorships are tax deductible. Details are posted on my personal fundraising website https://pages.mwoy.org/soh/dayton18/skathula. I really appreciate your time and consideration.
Come on…let us be part of the “cure”!
Satheesh Kathula, MD, FACP
Clinical Professor of Medicine
2018 Man of the Year Candidate for Leukemia & Lymphoma Society
Partner Physician, Dayton Physicians, LLC.
A clinical study is a carefully conducted, controlled investigation used to uncover more effective ways to prevent, diagnose, treat, and understand human disease. As of February 2018, ClinicalTrials.gov lists more than 265,600 clinical research studies going on in the United States and 203 other countries.
Performed by both public and private research organizations using volunteer patients, the focus can vary greatly from clinical drug trials and behavioral studies, to new surgical procedures or medical devices. To participate, patients must meet the proper inclusive criteria for the study and are provided with details as to the purpose, benefits, and potential risks involved.
Once accepted into the program, patients are given a specific protocol to follow, and the research team monitors the results over a specific time. After completion, the results from test sites around the world are compiled by the study sponsor and made available to the entire medical research community.
Dayton Physicians Network is leading the way in clinical research as the first site to open and enroll patients in a new, worldwide cancer study. The DPN trial is a phase III, hepatocellular (liver) cancer research study to examine the use of a new type of medication that works in a different way than those currently available.
Joshua Cox, Pharm. D., is a board-certified pharmacotherapy specialist and the director of pharmacy and research at Dayton Physicians Network. Cox and his team at DPN’s Clinical Research Center are giving patients right here in the Miami Valley access to the latest cancer research, even before it’s available at any other cancer center in the world.
“Most people think that, in order to participate in a clinical trial, you must go to somewhere like Mayo Clinic to access the most progressive and innovative research, but that isn’t the case,” Cox says. DPN has created this new clinical research program for patients who have used traditional therapies and would like access to the most recent therapeutic breakthroughs and technology.
Dayton Physicians Network is a progressive organization, building a robust, innovative cancer research program here in Dayton. As the first to open the liver cancer study, our program offers patients direct and local access to a rapidly changing medical research landscape.
The clinical program also has helped to establish Dayton Physicians Network as a player on the world stage of oncology and hematology research. Besides the benefit to Dayton-area patients, DPN’s clinical research also advances knowledge and patient care methods used by the worldwide scientific community for all types of cancer.
“There are many privately owned oncology practices around the country but few that are as progressive and involved as we are,” Cox says. “Not only is it something to be proud of that we have that level of advanced care here in Dayton, but also to recognize that it’s available close to home.”
Oncology treatments are improving at a breakneck pace, and Dayton Physicians Network is working to bring patients the latest research and the highest-quality care. If you or a loved one needs an oncologist or hematologist, you can be confident that Dayton has available world-class treatment equal to that of the larger, more commonly known facilities in Columbus or Cleveland.
Dayton Physicians Network is conducting a wide range of clinical trials on many types of cancer, including breast, prostate, and liver. Patients interested in participating should contact the research coordinator at the Clinical Research Center at 937-771-2287937-771-2287, or visit the Research Center’s website.
As we strive for cutting edge treatments and look for new opportunities to serve our patients, we are excited to announce Dayton Physicians Research Center is the first research site in the world to open a new Phase III clinical trial for hepatocellular cancer and we have enrolled the first patient on this trial!
Mark Monsour, MD, is a specialist associated with the Urology and Robotics department of Dayton Physicians Network. Since 2005, he has served as Chief of Urology at MVH where he helped initiate the robotics program, and URONAV, a specialized 3T MRI system targeting prostate biopsies. He is past-president of the co-management group for Miami Valley South Surgery. He received his undergraduate degree from the the U.D and his medical degree at the University of Lousiville. He received postgraduate education at TempleUniversity Hospital. He is the author or co-author of numerous clinical publications and presentations on urological research in adults and children. He is married with two children and lives in Springboro.